Name | Number of supported studies | Average coverage | |
---|---|---|---|
astrocyte | 15 studies | 30% ± 14% | |
retinal cone cell | 6 studies | 25% ± 7% | |
interneuron | 3 studies | 27% ± 13% |
Insufficient scRNA-seq data for expression of ELOVL2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 99% | 1576.45 | 2627 / 2642 | 89% | 53.40 | 629 / 705 |
liver | 97% | 1207.39 | 220 / 226 | 91% | 66.31 | 369 / 406 |
prostate | 75% | 321.40 | 184 / 245 | 90% | 32.99 | 450 / 502 |
breast | 46% | 398.33 | 213 / 459 | 60% | 42.48 | 674 / 1118 |
skin | 17% | 57.44 | 310 / 1809 | 70% | 47.68 | 331 / 472 |
heart | 84% | 286.07 | 723 / 861 | 0% | 0 | 0 / 0 |
pancreas | 68% | 163.69 | 223 / 328 | 7% | 0.86 | 13 / 178 |
thymus | 60% | 151.62 | 393 / 653 | 7% | 0.55 | 41 / 605 |
adrenal gland | 17% | 34.86 | 45 / 258 | 31% | 3.21 | 72 / 230 |
bladder | 38% | 367.19 | 8 / 21 | 6% | 0.78 | 28 / 504 |
adipose | 27% | 64.98 | 330 / 1204 | 0% | 0 | 0 / 0 |
uterus | 6% | 13.67 | 11 / 170 | 16% | 2.43 | 75 / 459 |
lung | 8% | 21.28 | 49 / 578 | 12% | 2.28 | 144 / 1155 |
blood vessel | 18% | 48.17 | 246 / 1335 | 0% | 0 | 0 / 0 |
kidney | 0% | 0 | 0 / 89 | 18% | 2.01 | 162 / 901 |
intestine | 15% | 35.90 | 147 / 966 | 2% | 0.32 | 13 / 527 |
esophagus | 12% | 24.44 | 168 / 1445 | 5% | 2.29 | 10 / 183 |
ovary | 5% | 9.08 | 9 / 180 | 8% | 0.83 | 34 / 430 |
tonsil | 0% | 0 | 0 / 0 | 9% | 2.20 | 4 / 45 |
stomach | 4% | 7.40 | 14 / 359 | 4% | 1.02 | 12 / 286 |
lymph node | 0% | 0 | 0 / 0 | 7% | 0.99 | 2 / 29 |
muscle | 3% | 6.84 | 28 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 3% | 0.43 | 2 / 80 |
spleen | 0% | 1.20 | 1 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0.50 | 2 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0030148 | Biological process | sphingolipid biosynthetic process |
GO_0042761 | Biological process | very long-chain fatty acid biosynthetic process |
GO_0034626 | Biological process | fatty acid elongation, polyunsaturated fatty acid |
GO_0036109 | Biological process | alpha-linolenic acid metabolic process |
GO_0019367 | Biological process | fatty acid elongation, saturated fatty acid |
GO_0043651 | Biological process | linoleic acid metabolic process |
GO_0034625 | Biological process | fatty acid elongation, monounsaturated fatty acid |
GO_0035338 | Biological process | long-chain fatty-acyl-CoA biosynthetic process |
GO_0006636 | Biological process | unsaturated fatty acid biosynthetic process |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005515 | Molecular function | protein binding |
GO_0009922 | Molecular function | fatty acid elongase activity |
Gene name | ELOVL2 |
Protein name | Very long chain fatty acid elongase 2 (EC 2.3.1.199) (3-keto acyl-CoA synthase ELOVL2) (ELOVL fatty acid elongase 2) (ELOVL FA elongase 2) (Elongation of very long chain fatty acids protein 2) (Very long chain 3-ketoacyl-CoA synthase 2) (Very long chain 3-oxoacyl-CoA synthase 2) |
Synonyms | ELG3 SSC2 |
Description | FUNCTION: Catalyzes the first and rate-limiting reaction of the four reactions that constitute the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids (VLCFAs) per cycle. Condensing enzyme that catalyzes the synthesis of polyunsaturated very long chain fatty acid (C20- and C22-PUFA), acting specifically toward polyunsaturated acyl-CoA with the higher activity toward C20:4(n-6) acyl-CoA. May participate in the production of polyunsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators. . |
Accessions | Q9NXB9 ENST00000354666.4 |